Literature DB >> 1812630

Intravenous immune globulin use in patients with human immunodeficiency virus-related thrombocytopenia who require dental extraction.

M U Rarick1, P Burian, N de Guzman, B Espina, T Montgomery, D Jamin, A M Levine.   

Abstract

Five patients with human immunodeficiency virus (HIV)-related immune thrombocytopenia who were undergoing dental extraction were treated with intravenous immune globulin (IVIG). All patients received IVIG, 1 gram per kg, the day before the dental extraction and again the day of the dental extraction. Four patients had a previous history of minor clinical bleeding. The median baseline platelet count before extraction was 20 X 10(9) per liter (range 13 to 44). The median peak platelet count was 100 X 10(9) per liter (range 56 to 528) following infusion. This peak response was achieved by day 2 in 3 patients and by days 5 and 7 in 1 patient each. No patients had complications or toxicity from the infusions or perioperative bleeding. No patients required blood product transfusions for the surgical procedure. In conclusion, IVIG infusion should be considered in patients with HIV-related immune thrombocytopenia requiring surgical procedures when a prompt rise in platelet count is desired.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1812630      PMCID: PMC1003106     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  21 in total

1.  Immune thrombocytopenia gammaglobulin, and positivity to the human T-lymphotropic virus type III.

Authors:  Y Laurian; P Le Bras; A Ellrodt; P Alvin
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

2.  Splenectomy. The treatment of choice for human immunodeficiency virus-related immune thrombocytopenia?

Authors:  T S Ravikumar; J D Allen; A Bothe; G Steele
Journal:  Arch Surg       Date:  1989-05

3.  Treatment of Kaposi's sarcoma and thrombocytopenia with vincristine in patients with the acquired immunodeficiency syndrome.

Authors:  D M Mintzer; F X Real; L Jovino; S E Krown
Journal:  Ann Intern Med       Date:  1985-02       Impact factor: 25.391

4.  Zidovudine for thrombocytopenic purpura related to human immunodeficiency virus (HIV) infection.

Authors:  E Oksenhendler; P Bierling; F Ferchal; J P Clauvel; M Seligmann
Journal:  Ann Intern Med       Date:  1989-03-01       Impact factor: 25.391

5.  The effect of azidothymidine on HIV-related thrombocytopenia.

Authors:  K B Hymes; J B Greene; S Karpatkin
Journal:  N Engl J Med       Date:  1988-02-25       Impact factor: 91.245

6.  Antibodies to human T-lymphotropic virus type III and development of the acquired immunodeficiency syndrome in homosexual men presenting with immune thrombocytopenia.

Authors:  D I Abrams; D D Kiprov; J J Goedert; M G Sarngadharan; R C Gallo; P A Volberding
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

7.  Anti-RH immunoglobulin therapy for human immunodeficiency virus-related immune thrombocytopenic purpura.

Authors:  E Oksenhendler; P Bierling; Y Brossard; C Schenmetzler; P M Girard; M Seligmann; J P Clauvel
Journal:  Blood       Date:  1988-05       Impact factor: 22.113

8.  Thrombocytopenia in homosexual patients. Prognosis, response to therapy, and prevalence of antibody to the retrovirus associated with the acquired immunodeficiency syndrome.

Authors:  C Walsh; R Krigel; E Lennette; S Karpatkin
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

9.  Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA.

Authors:  D Zucker-Franklin; Y Z Cao
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Treatment of human immunodeficiency virus-related thrombocytopenia with zidovudine.

Authors:  J C Pottage; C A Benson; J B Spear; A L Landay; H A Kessler
Journal:  JAMA       Date:  1988-11-25       Impact factor: 56.272

View more
  2 in total

Review 1.  Does intravenous immune globulin have a role in HIV-infected patients?

Authors:  P L Yap
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

2.  Chimeric SCID-hu Model as a Human Hematopoietic Stem Cell Host That Recapitulates the Effects of HIV-1 on Bone Marrow Progenitors in Infected Patients.

Authors:  I Birgitta Sundell; Prasad S Koka
Journal:  J Stem Cells       Date:  2006
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.